GREY:TSTIF - Post by User
Post by
echo2on Sep 13, 2017 9:30am
207 Views
Post# 26689177
TSO3 Has Posted a New Presentation on Website
TSO3 Has Posted a New Presentation on Websitehttps://www.tso3.com/media/application/media/Corporate%20Presentation%20(September%202017).pdf
Again, while this is just an excellent summary, it is worth a read for all investors.
Reviewing the timeline posted in the presentation, and given the strong likelihood of the (TSO3 friendly) FDA imminently approving the VP4 for terminally sterilizing duodenoscopes, (given approvals elsewhere, and now the fact that the second largest hospital in Canada is using a couple of VP4's to exclusively sterilize duodenoscopes, thus validating and establishing a new standard of care), I wonder at what point US government payers (Medicare, Medicaid, etc.) to hospitals, GI suites, health care providers (in light of starkly increased costs to the system and to patients resulting from the ongoing contamination and infection problems) will start to pay less financial reimbursement to those who do not use the new standard of care...? This reimbursement discussion and, of course, any implementation, will irreversibly change the sterilization and scopes industries as much or more than Spaulding Classification changes toward sterilization of scopes, etc..